BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392:2313-2324. [PMID: 30496122 DOI: 10.1016/s0140-6736(18)31865-8] [Cited by in Crossref: 224] [Cited by in F6Publishing: 236] [Article Influence: 74.7] [Reference Citation Analysis]
Number Citing Articles
1 Bhargava S, Bhavna, Sethiya N, Dhara AK, Sahoo J, Chitme H, Gupta M, Upreti N, Ahmad Y. Clinical Trials and Regulatory considerations of Antiviral agents. Viral Infections and Antiviral Therapies 2023. [DOI: 10.1016/b978-0-323-91814-5.00021-0] [Reference Citation Analysis]
2 Pan Y, Guo J, Hu N, Xun Y, Zhang B, Feng Q, Chen S, Li X, Liu Q, Hu Y, Zhao Y. Distinct common signatures of gut microbiota associated with damp-heat syndrome in patients with different chronic liver diseases. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1027628] [Reference Citation Analysis]
3 Nakanishi A, Okumura H, Hashita T, Yamashita A, Nishimura Y, Watanabe C, Kamimura S, Hayashi S, Murakami S, Ito K, Iwao T, Ikeda A, Hirose T, Sunazuka T, Tanaka Y, Matsunaga T. Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2. Viruses 2022;14:2468. [DOI: 10.3390/v14112468] [Reference Citation Analysis]
4 He Z, Zhou J, Tian Y, Wu S, Sun Y, Ou X, Jia J, Wang B, Wu X, You H. Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis. Scand J Gastroenterol 2022;:1-9. [PMID: 36227688 DOI: 10.1080/00365521.2022.2132532] [Reference Citation Analysis]
5 Liu CH, Jiang W, Wu DB, Zeng QM, Wang YJ, Tang H. Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection. Dig Dis Sci 2022. [PMID: 36227429 DOI: 10.1007/s10620-022-07695-2] [Reference Citation Analysis]
6 Hui RW, Mak L, Cheung K, Fung J, Seto W, Yuen M. Novel Combination Strategies With Investigational Agents for Functional Cure of Chronic Hepatitis B Infection. Curr Hepatology Rep 2022. [DOI: 10.1007/s11901-022-00590-4] [Reference Citation Analysis]
7 Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. World J Clin Cases 2022; 10(28): 10085-10096 [DOI: 10.12998/wjcc.v10.i28.10085] [Reference Citation Analysis]
8 Mokhtari F, Kaboosi H, Mohebbi SR, Asadzadeh Aghdaei H, Zali MRZ, Department of Microbiology, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran, Department of Microbiology, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Evaluation of Circulating MicroRNA-222 in Patients with Chronic Hepatitis B virus Infection as a Potential Noninvasive Diagnostic Biomarker. Iran J Med Microbiol 2022;16:543-550. [DOI: 10.30699/ijmm.16.6.543] [Reference Citation Analysis]
9 Li G, Wang Z, Chen D, Yin J, Mo Z, Sun B, Yang T, Zhang X, Zhai Z, Li Y, Chen P, Dai Y, Wang Z, Ma J. Comprehensive analysis of a TPX2-related TRHDE-AS1/PKIA ceRNA network involving prognostic signatures in Hepatitis B virus-infected hepatocellular carcinoma. Front Cell Infect Microbiol 2022;12:1025900. [DOI: 10.3389/fcimb.2022.1025900] [Reference Citation Analysis]
10 Hu Q, Qi X, Yu Y, Gao Y, Zhang X, Wang Q, Zhang X, Zhuo Y, Li J, Zhang J, Chen L, Huang Y. The efficacy and safety of adding on or switching to peginterferon α-2b in HBeAg-positive chronic hepatitis B patients with long-term entecavir treatment: A multicentre randomised controlled trial. Aliment Pharmacol Ther 2022. [PMID: 36128636 DOI: 10.1111/apt.17222] [Reference Citation Analysis]
11 Huang X, Mo Q, Fu T, Liu Y, Diao B. STAT1 is associated with NK cell dysfunction by downregulating NKG2D transcription in chronic HBV-infected patients. Immunobiology 2022;227:152272. [PMID: 36122437 DOI: 10.1016/j.imbio.2022.152272] [Reference Citation Analysis]
12 Luo M, Jiang DK. Editorial: tripartite motif 26 inhibits hepatitis B virus replication and its genetic polymorphism predicts response to interferon treatment-towards a better understanding of interferon responsiveness in chronic hepatitis B. Authors' reply. Aliment Pharmacol Ther 2022;56:1096-7. [PMID: 35995749 DOI: 10.1111/apt.17181] [Reference Citation Analysis]
13 Varghese CS, Parish JL, Ferguson J. Lying low-chromatin insulation in persistent DNA virus infection. Curr Opin Virol 2022;55:101257. [PMID: 35998396 DOI: 10.1016/j.coviro.2022.101257] [Reference Citation Analysis]
14 Yan M, Hu D, Wu Z, Lai J, Zhang L, Zhang H, Li S, Bai L. Survival Fate of Hepatic Stem/Progenitor and Immune Cells in a Liver Fibrosis/Cirrhosis Animal Model and Clinical Implications. Animal Models and Experimental Research in Medicine [Working Title] 2022. [DOI: 10.5772/intechopen.106220] [Reference Citation Analysis]
15 Yang W, Tian X, Liang J. A Comprehensive Nursing Model Combined with High-Quality Nursing Intervention for Antiviral Therapy in Patients with Chronic Hepatitis B. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-7. [DOI: 10.1155/2022/6244637] [Reference Citation Analysis]
16 Hyrina A, Burdette D, Song Z, Ramirez R, Okesli-armlovich A, Vijayakumar A, Bates J, Trevaskis JL, Fletcher SP, Lee WA, Holdorf MM. Targeting lipid biosynthesis pathways for hepatitis B virus cure. PLoS ONE 2022;17:e0270273. [DOI: 10.1371/journal.pone.0270273] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Lau FF, Bollerup S, Engsig F, Krarup H, Mygind LH, Hansen JB, Madsen LG, Thielsen P, Balslev U, Nielsen LN, Barfod TS, Clausen MR, Hobolth L, Laursen AL, Tarp B, Roege BT, Gerstoft J, Christensen PB, Weis N. Ischemic Heart Disease in Chronic Hepatitis B: A Danish Nationwide Cohort Study. Clin Epidemiol 2022;14:879-88. [PMID: 35879942 DOI: 10.2147/CLEP.S361910] [Reference Citation Analysis]
18 Dong H, Hong X, He Y, Bao Z, Zhang Y, Shen S, Wang G, Zhang J, Mo R. A carrier-free metal-organic hybrid nanoassembly with combination anti-viral and hepato-protective activity for hepatitis B treatment. Biomater Sci 2022;10:4356-66. [PMID: 35786722 DOI: 10.1039/d2bm00407k] [Reference Citation Analysis]
19 Quan M, Liu X, Liu C, Li W, Xing H, Pan JS. Antiviral Therapy for Prevention of Perinatal Hepatitis B Virus Transmission Reduces the Incidence of Postpartum Hepatitis Flare. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/7046955] [Reference Citation Analysis]
20 Shiue SJ, Cheng CL, Shiue HS, Chen CN, Cheng SW, Wu LW, Jargalsaikhan G, Chan TS, Lin HY, Wu MS. Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile. Nutrients 2022;14:2790. [PMID: 35889747 DOI: 10.3390/nu14142790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Qin L, Liu Y, Xu Y, Li Y, Hu J, Ju Y, Zhang Y, Wang S, Li Z, Li C, Li X, Meng S. MHC Class I Assembly Function and Intracellular Transport Routes for Hepatitis B Virus Antigen Cross-presentation by Heat Shock Protein gp96. Infectious Diseases & Immunity 2022;2:183-192. [DOI: 10.1097/id9.0000000000000058] [Reference Citation Analysis]
22 Schlegel MK, Janas MM, Jiang Y, Barry JD, Davis W, Agarwal S, Berman D, Brown CR, Castoreno A, LeBlanc S, Liebow A, Mayo T, Milstein S, Nguyen T, Shulga-Morskaya S, Hyde S, Schofield S, Szeto J, Woods LB, Yilmaz VO, Manoharan M, Egli M, Charissé K, Sepp-Lorenzino L, Haslett P, Fitzgerald K, Jadhav V, Maier MA. From bench to bedside: Improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization. Nucleic Acids Res 2022:gkac539. [PMID: 35736224 DOI: 10.1093/nar/gkac539] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Popa GL, Popa MI. Oxidative Stress in Chronic Hepatitis B—An Update. Microorganisms 2022;10:1265. [DOI: 10.3390/microorganisms10071265] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Quan M, Liu C, Li W, Xing H, Fan Y. Antiviral Therapy for a Postpartum Flare in Women with Chronic HBV Infection Shortens the ALT Recovery Time and Reduces Hepatitis Re-Flare Rates within 4 years. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-9. [DOI: 10.1155/2022/4753267] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Liu Y, Du X, Lu J, Ma L, Jing Y, Ben H, Chen X, Zhang J. B10 Cells Are Associated With Clinical Prognosis During Adult Symptomatic Acute HBV Infection. Front Immunol 2022;13:906650. [DOI: 10.3389/fimmu.2022.906650] [Reference Citation Analysis]
26 Li Y, He M, Gong R, Wang Z, Lu L, Peng S, Duan Z, Feng Y, Liu Y, Gao B. Forkhead O Transcription Factor 4 Restricts HBV Covalently Closed Circular DNA Transcription and HBV Replication through Genetic Downregulation of Hepatocyte Nuclear Factor 4 Alpha and Epigenetic Suppression of Covalently Closed Circular DNA via Interacting with Promyelocytic Leukemia Protein. J Virol 2022;:e0054622. [PMID: 35695580 DOI: 10.1128/jvi.00546-22] [Reference Citation Analysis]
27 Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, Corral O, Soriano V. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. Hepatol Int 2022. [PMID: 35666390 DOI: 10.1007/s12072-022-10365-0] [Reference Citation Analysis]
28 Al-ismaili OM, Al-jardani A, Al-hinai F, Al-shukri I, Mathew M, Al-abri S, Al-kindi H. Prevalence of Hepatitis B Infection Among Pregnant Women in Oman. J Epidemiol Glob Health. [DOI: 10.1007/s44197-022-00043-7] [Reference Citation Analysis]
29 Chu Q, Li J, Chen J, Yuan Z. HBV induced the discharge of intrinsic antiviral miRNAs in HBV-replicating hepatocytes via extracellular vesicles to facilitate its replication. J Gen Virol 2022;103. [PMID: 35604380 DOI: 10.1099/jgv.0.001744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Xu M, Guan X. Aurintricarboxylic Acid Suppresses Hepatitis B Virus Replication by Inhibition of RNase H Activity. Front Virol 2022;2. [DOI: 10.3389/fviro.2022.861494] [Reference Citation Analysis]
31 Caviglia GP, Ribaldone DG. Special Issue "Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice". J Clin Med 2022;11:2797. [PMID: 35628924 DOI: 10.3390/jcm11102797] [Reference Citation Analysis]
32 Hui RW, Mak LY, Seto WK, Yuen MF. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: A spotlight on drugs at phase II clinical trials. Expert Opin Emerg Drugs 2022. [PMID: 35511483 DOI: 10.1080/14728214.2022.2074977] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Wang T, Hu L, Lu J, Xiao M, Liu J, Xia H, Lu H. Functional metabolomics revealed functional metabolic-characteristics of chronic hepatitis that is significantly differentiated from acute hepatitis in mice. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106248] [Reference Citation Analysis]
34 Duan T, Jiang HY, Ling WW, Song B. Noninvasive imaging of hepatic dysfunction: A state-of-the-art review. World J Gastroenterol 2022; 28(16): 1625-1640 [DOI: 10.3748/wjg.v28.i16.1625] [Reference Citation Analysis]
35 Zhou YG, Tian N, Xie WN. Total cholesterol to high-density lipoprotein ratio and nonalcoholic fatty liver disease in a population with chronic hepatitis B. World J Hepatol 2022; 14(4): 791-801 [DOI: 10.4254/wjh.v14.i4.791] [Reference Citation Analysis]
36 Yuen MF, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Sulkowski MS. Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection. J Hepatol 2022:S0168-8278(22)00238-0. [PMID: 35460726 DOI: 10.1016/j.jhep.2022.04.005] [Reference Citation Analysis]
37 Ghany MG, Liang TJ. Acute viral hepatitis. In: Wang TC, Camilleri M, Lebwohl B, Lok AS, Sandborn WJ, Wang KK, Wu GD, editors. Yamada's Textbook of Gastroenterology. Wiley; 2022. pp. 1804-40. [DOI: 10.1002/9781119600206.ch86] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Chu JN, Nguyen TT, Rivadeneira NA, Hiatt RA, Sarkar U. Exploring factors associated with hepatitis B screening in a multilingual and diverse population. BMC Health Serv Res 2022;22:479. [PMID: 35410249 DOI: 10.1186/s12913-022-07813-w] [Reference Citation Analysis]
39 Zhang C, Li J, Cheng Y, Meng F, Song JW, Fan X, Fan H, Li J, Fu YL, Zhou MJ, Hu W, Wang SY, Fu YJ, Zhang JY, Xu RN, Shi M, Hu X, Zhang Z, Ren X, Wang FS. Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients. Gut 2022:gutjnl-2021-325915. [PMID: 35361683 DOI: 10.1136/gutjnl-2021-325915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Lan W, Wang Y, Zhou Z, Sun X, Zhang Y, Zhang F. Metabolic Regulation of Hepatitis B Virus Infection in HBV-Transgenic Mice. Metabolites 2022;12:287. [DOI: 10.3390/metabo12040287] [Reference Citation Analysis]
41 Zong N, Gao Y, Chen Y, Luo X, Jiang X. Automated Centrifugal Microfluidic Chip Integrating Pretreatment and Molecular Diagnosis for Hepatitis B Virus Genotyping from Whole Blood. Anal Chem 2022. [PMID: 35289612 DOI: 10.1021/acs.analchem.2c00337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
42 Li X, Zhang Z, Chen Y, Wang B, Yang G, Xu X, Yechao B, Bai D, Feng B, Mao Y, Feng J, Bai C, He F, Tao W. Discovery of SHR5133, a Highly Potent and Novel HBV Capsid Assembly Modulator. ACS Med Chem Lett 2022;13:507-12. [PMID: 35300087 DOI: 10.1021/acsmedchemlett.2c00002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Albuquerque-Souza E, Sahingur SE. Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis. Periodontol 2000 2022. [PMID: 35244954 DOI: 10.1111/prd.12427] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
44 Taniki N, Nakamoto N, Chu PS, Ichikawa M, Teratani T, Kanai T. Th17 cells in the liver: balancing autoimmunity and pathogen defense. Semin Immunopathol 2022. [PMID: 35211777 DOI: 10.1007/s00281-022-00917-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Huang Y, Zheng S, Guo Z, de Mollerat du Jeu X, Liang X, Yang Z, Zhang H, Gao S, Liang Z. Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-021-00859-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Su S, Wong WC, Zou Z, Cheng DD, Ong JJ, Chan P, Ji F, Yuen M, Zhuang G, Seto W, Zhang L. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. The Lancet Global Health 2022;10:e278-87. [DOI: 10.1016/s2214-109x(21)00517-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
47 Krag A, Roskams T, Pinzani M, Mueller S. Diagnostic challenges in patients with alcohol-related liver disease. Z Gastroenterol 2022;60:45-57. [PMID: 35042253 DOI: 10.1055/a-1713-4372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Mathew E, Stewart SA, Utomo E, Larrañeta E, Lamprou DA. Implantable and long-lasting drug delivery systems for infectious, inflammatory, endocrine, and neurodegenerative diseases. Long-Acting Drug Delivery Systems 2022. [DOI: 10.1016/b978-0-12-821749-8.00003-3] [Reference Citation Analysis]
49 Gish RG, Asselah T, Squires K, Mayers D. Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens. Antivir Chem Chemother 2022;30:204020662211387. [DOI: 10.1177/20402066221138705] [Reference Citation Analysis]
50 Shirmast P, Shahri MA, Pashangzadeh S, Mirshahabi H, Samadi E, Motamed N. Detection of occult hepatitis B virus in patients undergoing chemotherapy in Iran. Future Virology 2022;17:29-36. [DOI: 10.2217/fvl-2020-0386] [Reference Citation Analysis]
51 Duan Y, Chen Z, Li H, Shen W, Zeng Y, Peng M, Hu P. Potential Molecular Targets of Tenofovir Disoproxil Fumarate for Alleviating Chronic Liver Diseases via a Non-Antiviral Effect in a Normal Mouse Model. Front Mol Biosci 2021;8:763150. [PMID: 34869594 DOI: 10.3389/fmolb.2021.763150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Qu J, Liu Q, You G, Ye L, Jin Y, Kong L, Guo W, Xu Q, Sun Y. Advances in ameliorating inflammatory diseases and cancers by andrographolide: Pharmacokinetics, pharmacodynamics, and perspective. Med Res Rev 2021. [PMID: 34877672 DOI: 10.1002/med.21873] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
53 Li J, Chen H, Chen J, Zhou B, Hou J, Jiang DK. A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B. Pharmgenomics Pers Med 2021;14:1505-15. [PMID: 34848996 DOI: 10.2147/PGPM.S337962] [Reference Citation Analysis]
54 Kremsdorf D, Lekbaby B, Bablon P, Sotty J, Augustin J, Schnuriger A, Pol J, Soussan P. Alternative splicing of viral transcripts: the dark side of HBV. Gut 2021;70:2373-82. [PMID: 34535538 DOI: 10.1136/gutjnl-2021-324554] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
55 Martini F, Champagne E. The Contribution of Human Herpes Viruses to γδ T Cell Mobilisation in Co-Infections. Viruses 2021;13:2372. [PMID: 34960641 DOI: 10.3390/v13122372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Giadans CG, Ríos DA, Ameigeiras B, Haddad L, De Matteo EN, Valva P, Preciado MV. Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same. J Viral Hepat 2021. [PMID: 34820942 DOI: 10.1111/jvh.13635] [Reference Citation Analysis]
57 Lu CM, Cheng JS, Sun WC, Chen WC, Tsay FW, Wang HM, Tsai TJ, Kao SS, Li YD, Li YR, Lin HS, Yin CH, Tsai WL. Tenofovir versus lamivudine followed by tenofovir in severe exacerbation of hepatitis B: a randomized controlled study. Antimicrob Agents Chemother 2021;:AAC0166421. [PMID: 34807763 DOI: 10.1128/AAC.01664-21] [Reference Citation Analysis]
58 Li Y, He M, Wang Z, Duan Z, Guo Z, Wang Z, Gong R, Chu T, Cai J, Gao B. STING signaling activation inhibits HBV replication and attenuates the severity of liver injury and HBV-induced fibrosis. Cell Mol Immunol 2021. [PMID: 34811496 DOI: 10.1038/s41423-021-00801-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
59 Chen Y, Wei D, Deng M. Comparative Analysis of Serum Proteins Between Hepatitis B Virus Genotypes B and C Infection by DIA-Based Quantitative Proteomics. Infect Drug Resist 2021;14:4701-15. [PMID: 34795487 DOI: 10.2147/IDR.S335666] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Liu J, Wang J, Yan X, Xue R, Zhan J, Jiang S, Geng Y, Liu Y, Mao M, Xia J, Yin S, Tong X, Chen Y, Ding W, Huang R, Wu C. Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis. Hepatol Commun 2021. [PMID: 34783181 DOI: 10.1002/hep4.1859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
61 Huang X, Zheng X, Shen C. Antiviral Therapy with Entecavir following Antituberculosis Therapy Alleviates Liver Injury and Restores Innate Immunity in Tuberculosis Patients Coinfected with Hepatitis B Virus. Evid Based Complement Alternat Med 2021;2021:2884151. [PMID: 34764998 DOI: 10.1155/2021/2884151] [Reference Citation Analysis]
62 Zhang Q, Cai DC, Hu P, Ren H. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. Chin Med J (Engl) 2021;134:2810-7. [PMID: 34759219 DOI: 10.1097/CM9.0000000000001793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
64 Miao J, Gao P, Li Q, He K, Zhang L, Wang J, Huang L. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int J Mol Sci 2021;22:11227. [PMID: 34681886 DOI: 10.3390/ijms222011227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Liu T, Li W, Zhang Y, Siyin ST, Zhang Q, Song M, Zhang K, Liu S, Shi H. Associations between hepatitis B virus infection and risk of colorectal Cancer: a population-based prospective study. BMC Cancer 2021;21:1119. [PMID: 34663268 DOI: 10.1186/s12885-021-08846-w] [Reference Citation Analysis]
66 Safari JB, Bapolisi AM, Krause RWM. Development of pH-Sensitive Chitosan-g-poly(acrylamide-co-acrylic acid) Hydrogel for Controlled Drug Delivery of Tenofovir Disoproxil Fumarate. Polymers (Basel) 2021;13:3571. [PMID: 34685332 DOI: 10.3390/polym13203571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 84] [Cited by in F6Publishing: 99] [Article Influence: 84.0] [Reference Citation Analysis]
68 Gane E, Yuen MF, Kim DJ, Chan HL, Surujbally B, Pavlovic V, Das S, Triyatni M, Kazma R, Grippo JF, Buatois S, Lemenuel-Diot A, Krippendorff BF, Mueller H, Zhang Y, Kim HJ, Leerapun A, Lim TH, Lim YS, Tanwandee T, Kim W, Cheng W, Hu TH, Wat C. Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. Hepatology 2021;74:1795-808. [PMID: 34037271 DOI: 10.1002/hep.31920] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
69 Du Y, Yang X, Li J, Sokolova V, Zou S, Han M, Yan H, Wey K, Lu M, Dittmer U, Yang D, Epple M, Wu J. Delivery of toll-like receptor 3 ligand poly(I:C) to the liver by calcium phosphate nanoparticles conjugated with an F4/80 antibody exerts an anti-hepatitis B virus effect in a mouse model. Acta Biomater 2021;133:297-307. [PMID: 33540061 DOI: 10.1016/j.actbio.2021.01.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
70 Lim MS, Goh GB, Chang JP, Low JK, Shelat VG, Huey TC, Dan YY, Kow A, Shridhar I, Tan PS, Junnarkar SP, Tan CK. A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade. JGH Open 2021;5:1015-8. [PMID: 34584969 DOI: 10.1002/jgh3.12624] [Reference Citation Analysis]
71 Bazinet M, Anderson M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Vaillant A. Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy. Hepatol Commun 2021;5:1873-87. [PMID: 34558823 DOI: 10.1002/hep4.1767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
72 Yuan Q, Haque O, Hong S, Ortiz A, Bethea ED, Sise ME, Markmann JF, Elias N. Influence of donor and recipient hepatitis B virus infection on long-term outcomes after kidney transplantation. Clin Transplant 2021;:e14466. [PMID: 34545965 DOI: 10.1111/ctr.14466] [Reference Citation Analysis]
73 Huang CE, Chang JJ, Wu YY, Huang SH, Chen WM, Hsu CC, Lu CH, Hung CH, Shi CS, Lee KD, Chen CC, Chen MC. Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection. Biomed J 2021:S2319-4170(21)00113-X. [PMID: 34508913 DOI: 10.1016/j.bj.2021.09.001] [Reference Citation Analysis]
74 Lyalina LV, Esaulenko EV, Khorkova EV, Novak KE, Ostankova YV, Serikova EN, Vasilyev DV, Gorziy ES, Butskaya MJ, Kritskaya IV, Buts LV, Grebenkina EV, Baydakova EV, Smirnova NA, Krasnopyorova MA, Koltsov NS, Kotovich LM, Kalinina EL, Galimov RR, Kirkhar NV, Cherepanova EA, Totolian AA. Results of implementation of viral hepatitis B elimination program in the North-West Russia. Russian Journal of Infection and Immunity 2021;11:875-886. [DOI: 10.15789/2220-7619-rot-1785] [Reference Citation Analysis]
75 Zhu M, Hua T, Ouyang T, Qian H, Yu B. Applications of Mesenchymal Stem Cells in Liver Fibrosis: Novel Strategies, Mechanisms, and Clinical Practice. Stem Cells Int 2021;2021:6546780. [PMID: 34434239 DOI: 10.1155/2021/6546780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
76 Medas R, Liberal R, Macedo G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J Clin Cases 2021; 9(24): 6979-6986 [PMID: 34540953 DOI: 10.12998/wjcc.v9.i24.6979] [Reference Citation Analysis]
77 Zhang T, Zhang G, Deng X, Zeng J, Jin J, Zeping H, Wu M, Zheng R. APS (Age, Platelets, 2D Shear-Wave Elastography) Score Predicts Hepatocellular Carcinoma in Chronic Hepatitis B. Radiology 2021;301:350-9. [PMID: 34427463 DOI: 10.1148/radiol.2021204700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099 [PMID: 34497437 DOI: 10.3748/wjg.v27.i30.5088] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Li J, Meng F, Zheng J, Liang Q, Li H, Li J, Zhang L, Gan J, Zhu F. Immune persistence induced by three doses of 60 μg hepatitis B vaccine in non-responders following standard primary vaccination in Chinese adults. Hum Vaccin Immunother 2021;17:2762-7. [PMID: 33735590 DOI: 10.1080/21645515.2021.1877079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Lu H, Yi W, Sun F, Zeng Z, Zhang L, Li M, Xie Y. Comprehensive investigation of HBV-related hepatocellular carcinoma and choice of anti-HBV therapy. Biosafety and Health 2021;3:190-6. [DOI: 10.1016/j.bsheal.2021.05.001] [Reference Citation Analysis]
81 Zeng X, Yuan X, Cai Q, Tang C, Gao J. Circular RNA as An Epigenetic Regulator in Chronic Liver Diseases. Cells 2021;10:1945. [PMID: 34440714 DOI: 10.3390/cells10081945] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
82 Caviglia GP, Troshina Y, Garro E, Gesualdo M, Aneli S, Birolo G, Pittaluga F, Cavallo R, Saracco GM, Ciancio A. Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study. J Clin Med 2021;10:3308. [PMID: 34362093 DOI: 10.3390/jcm10153308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
83 Hong J, Choi Y, Choi Y, Lee J, Hong HJ. Epitope-Paratope Interaction of a Neutralizing Human Anti-Hepatitis B Virus PreS1 Antibody That Recognizes the Receptor-Binding Motif. Vaccines (Basel) 2021;9:754. [PMID: 34358170 DOI: 10.3390/vaccines9070754] [Reference Citation Analysis]
84 Rammohan A. Current management & future directions in post-liver transplant recurrence of viral hepatitis. Journal of Liver Transplantation 2021;3:100027. [DOI: 10.1016/j.liver.2021.100027] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Yu F, Li G, Hao W, Hu W. Hepatitis B Virus-Related Glomerulonephritis with Positive and Negative Serum HBsAg: Different Clinicopathologic Characteristics of Two Clinical Subtypes. Int J Gen Med 2021;14:3069-77. [PMID: 34234535 DOI: 10.2147/IJGM.S318087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Wang H, Chen XZ, Chen XL, Zhang WH, Liu K, Wang YJ, Tang HR, Hu JK; SIGES research group. Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital-based, case-control study (SIGES). Cancer Med 2021;10:3741-55. [PMID: 33934530 DOI: 10.1002/cam4.3901] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
87 Xu T, Wang P, Zheng X, Yan Z, Li K, Xu J, Jiang C, Zhu F. The therapeutic effects and mechanisms of Long Chai Fang on chronic hepatitis B. Ann Transl Med 2021;9:865. [PMID: 34164499 DOI: 10.21037/atm-21-1923] [Reference Citation Analysis]
88 Ma S, Xie Z, Zhang L, Yang Y, Jiang H, Ouyang X, Zhao Y, Liu Q, Xu X, Li L. Identification of a Potential miRNA-mRNA Regulatory Network Associated With the Prognosis of HBV-ACLF. Front Mol Biosci 2021;8:657631. [PMID: 33996909 DOI: 10.3389/fmolb.2021.657631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Wang J, Wu M, Linghu R, Chang J, Wu M, Feng C, Ren X, Liu C, Lin J, Song T, Gu J, Zhang Y, Fang Y, Ma S, Hu P, Wu L, Han X, Chen K, Shi Q, Zhang R, Zhou Q, Du R, Gao Y, Jing X, Yang S, Zhou C, Zheng J, Liang P, Zheng RQ. Usefulness of New Shear Wave Elastography Technique for Noninvasive Assessment of Liver Fibrosis in Patients with Chronic Hepatitis B: A Prospective Multicenter Study. Ultraschall Med 2021. [PMID: 33910257 DOI: 10.1055/a-1376-6734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
90 Senaweera S, Du H, Zhang H, Kirby KA, Tedbury PR, Xie J, Sarafianos SG, Wang Z. Discovery of New Small Molecule Hits as Hepatitis B Virus Capsid Assembly Modulators: Structure and Pharmacophore-Based Approaches. Viruses 2021;13:770. [PMID: 33925540 DOI: 10.3390/v13050770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
91 Li X, Liu X, Wang W. IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases. Front Cell Dev Biol 2021;9:614847. [PMID: 33777929 DOI: 10.3389/fcell.2021.614847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
92 Suares A, Medina MV, Coso O. Autophagy in Viral Development and Progression of Cancer. Front Oncol 2021;11:603224. [PMID: 33763351 DOI: 10.3389/fonc.2021.603224] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
93 Wang K, Yu Z, Huang Y, Yang K, He T, Xiao T, Yu Y, Li Y, Liu L, Xiong J, Zhao J. Clinicopathological features, risk factors, and outcomes of immunoglobulin A nephropathy associated with hepatitis B virus infection. J Nephrol 2021. [PMID: 33683672 DOI: 10.1007/s40620-021-01004-2] [Reference Citation Analysis]
94 Deng F, Xu G, Cheng Z, Huang Y, Ma C, Luo C, Yu C, Wang J, Xu X, Liu S, Zhu Y. Hepatitis B Surface Antigen Suppresses the Activation of Nuclear Factor Kappa B Pathway via Interaction With the TAK1-TAB2 Complex. Front Immunol 2021;12:618196. [PMID: 33717111 DOI: 10.3389/fimmu.2021.618196] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
95 Wu L, Xu W, Li X, Liu Y, Wang L, Zhu S, Yang F, Xie C, Peng L. The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment. Front Pharmacol 2021;12:616858. [PMID: 33716744 DOI: 10.3389/fphar.2021.616858] [Reference Citation Analysis]
96 Fei-Fei S, Xiao-Dan R, Hai-Qiang L, He-Wei Z. Value of anti-hepatitis B virus in serum tested by enzyme linked immunosorbent assay 3 in diagnosis of hepatitis B: A protocol for systemic review and meta analysis. Medicine (Baltimore) 2021;100:e23961. [PMID: 33545977 DOI: 10.1097/MD.0000000000023961] [Reference Citation Analysis]
97 Du Y, Yan H, Zou S, Khera T, Li J, Han M, Yang X, Wang B, Liu J, Sun S, Zheng X, Dittmer U, Lu M, Yang D, Wedemeyer H, Wu J. Natural Killer Cells Regulate the Maturation of Liver Sinusoidal Endothelial Cells Thereby Promoting Intrahepatic T-Cell Responses in a Mouse Model. Hepatol Commun 2021;5:865-81. [PMID: 34027274 DOI: 10.1002/hep4.1676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis 2021;8:2049936120985954. [PMID: 33614029 DOI: 10.1177/2049936120985954] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
99 Yu Z, Ma X, Zhang W, Chang X, An L, Niu M, Chen Y, Sun C, Yang Y. Microarray Data Mining and Preliminary Bioinformatics Analysis of Hepatitis D Virus-Associated Hepatocellular Carcinoma. Biomed Res Int 2021;2021:1093702. [PMID: 33564675 DOI: 10.1155/2021/1093702] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Caviglia GP, Armandi A, Rosso C, Ribaldone DG, Pellicano R, Fagoonee S. Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis. Diagnostics (Basel) 2021;11:187. [PMID: 33525443 DOI: 10.3390/diagnostics11020187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
101 Seto WK, Mandell MS. Chronic liver disease: Global perspectives and future challenges to delivering quality health care. PLoS One 2021;16:e0243607. [PMID: 33395423 DOI: 10.1371/journal.pone.0243607] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
102 Sonneveld MJ, van Meer S. Management of Patients With Chronic Hepatitis B (Hepadnaviridae) and Chronic Hepatitis D Infection (Deltavirus). Encyclopedia of Virology 2021. [DOI: 10.1016/b978-0-12-814515-9.00104-1] [Reference Citation Analysis]
103 Han JW, Shin EC. Liver-Resident Memory CD8+ T Cells: Possible Roles in Chronic HBV Infection. Int J Mol Sci 2020;22:E283. [PMID: 33396596 DOI: 10.3390/ijms22010283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
104 Cho YB, Lee IG, Joo YH, Hong SH, Seo YJ. TCR Transgenic Mice: A Valuable Tool for Studying Viral Immunopathogenesis Mechanisms. Int J Mol Sci 2020;21:E9690. [PMID: 33353154 DOI: 10.3390/ijms21249690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
105 Xu SH, Wu F, Guo LH, Zhang WB, Xu HX. Liver fibrosis index-based nomograms for identifying esophageal varices in patients with chronic hepatitis B related cirrhosis. World J Gastroenterol 2020; 26(45): 7204-7221 [PMID: 33362377 DOI: 10.3748/wjg.v26.i45.7204] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Cho IY, Chang Y, Sung E, Sohn W, Kang JH, Shin H, Ryu S. Depressive symptoms and risk of liver-related mortality in individuals with hepatitis B virus infection: a cohort study. Sci Rep 2020;10:20812. [PMID: 33257781 DOI: 10.1038/s41598-020-77886-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Jiang W, Wang L, Zhang Y, Li H. Circ-ATP5H Induces Hepatitis B Virus Replication and Expression by Regulating miR-138-5p/TNFAIP3 Axis. Cancer Manag Res 2020;12:11031-40. [PMID: 33173336 DOI: 10.2147/CMAR.S272983] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
108 Gudenkauf FJ, Thrift AP. Racial/Ethnic Differences in Cancers Attributable to Preventable Infectious Agents in Texas, 2015. Public Health Rep 2020;135:805-12. [PMID: 33080142 DOI: 10.1177/0033354920954497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Mahassadi AK, Team Machekam O, Attia AK. The Impact of Virologic Parameters and Liver Fibrosis on Health-Related Quality of Life in Black African Patients with Chronic Hepatitis B: Results from a High Endemic Area. Clin Exp Gastroenterol 2020;13:407-18. [PMID: 33061519 DOI: 10.2147/CEG.S255102] [Reference Citation Analysis]
110 Wang L, Hu H, Zhang R, Zheng X, Li J, Lu J, Zhang Y, Qi P, Lin W, Wu Y, Yu J, Fan J, Peng Y, Zheng H. Changes in the hepatitis B surface antibody in childhood acute lymphocytic leukaemia survivors after treatment with the CCLG-ALL 2008 protocol. Clin Exp Immunol 2021;203:80-6. [PMID: 32936935 DOI: 10.1111/cei.13513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Muraleedharan A, Bupesh G. A short note on HBV infection. Bioinformation 2020;16:505-8. [PMID: 32994674 DOI: 10.6026/97320630016505] [Reference Citation Analysis]
112 Li M, Zhang L, Lu Y, Chen Q, Lu H, Sun F, Zeng Z, Wan G, Zhao L, Xie Y. Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a. Virol Sin 2021;36:311-20. [PMID: 32975731 DOI: 10.1007/s12250-020-00290-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
113 Lu XJ, Yang XJ, Sun JY, Zhang X, Yuan ZX, Li XH. FibroBox: a novel noninvasive tool for predicting significant liver fibrosis and cirrhosis in HBV infected patients. Biomark Res 2020;8:48. [PMID: 33005419 DOI: 10.1186/s40364-020-00215-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
114 Mabunda N, Zicai AF, Ismael N, Vubil A, Mello F, Blackard JT, Lago B, Duarte V, Moraes M, Lewis L, Jani I. Molecular and serological characterization of occult hepatitis B among blood donors in Maputo, Mozambique. Mem Inst Oswaldo Cruz 2020;115:e200006. [PMID: 32997000 DOI: 10.1590/0074-02760200006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
115 Goverwa-Sibanda TP, Mupanguri C, Timire C, Harries AD, Ngwenya S, Chikwati E, Mapfuma C, Mushambi F, Tweya H, Ndlovu M. Hepatitis B infection in people living with HIV who initiate antiretroviral therapy in Zimbabwe. Public Health Action 2020;10:97-103. [PMID: 33134123 DOI: 10.5588/pha.20.0008] [Reference Citation Analysis]
116 Su DN, Wu SP, Xu SZ. Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis. Stem Cell Res Ther 2020;11:395. [PMID: 32928296 DOI: 10.1186/s13287-020-01911-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
117 Fan Y, Wang L, Ding Y, Sheng Q, Zhang C, Li Y, Han C, Dou X. Controlled attenuation parameter value-based diagnostic algorithm improves the accuracy of liver stiffness measurement in chronic hepatitis B patients. Aging (Albany NY) 2020;12:16072-82. [PMID: 32836216 DOI: 10.18632/aging.103522] [Reference Citation Analysis]
118 Verso MG, Costantino C, Marrella A, Immordino P, Vitale F, Amodio E. Kinetics of Anti-Hepatitis B Surface Antigen Titers in Nurse Students after a Two-Year Follow-Up. Vaccines (Basel) 2020;8:E467. [PMID: 32839391 DOI: 10.3390/vaccines8030467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Tang R, Lei Z, Wang X, Qi Q, He J, Liu D, Wang X, Chen X, Zhu J, Li Y, Zhou S, Su C. Hepatitis B envelope antigen increases Tregs by converting CD4+CD25- T cells into CD4+CD25+Foxp3+ Tregs. Exp Ther Med 2020;20:3679-86. [PMID: 32855720 DOI: 10.3892/etm.2020.9107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
120 Gish RG, Basit SA, Ryan J, Dawood A, Protzer U. Hepatitis B Core Antibody: Role in Clinical Practice in 2020. Curr Hepatology Rep 2020;19:254-65. [DOI: 10.1007/s11901-020-00522-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
121 Yuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J, Kim JH, Lik Yuen Chan H, Yoon KT, Klinker H, Manns M, Petersen J, Schluep T, Hamilton J, Given BD, Ferrari C, Lai CL, Locarnini SA, Gish RG. RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. Hepatology 2020;72:19-31. [PMID: 31654573 DOI: 10.1002/hep.31008] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 28.0] [Reference Citation Analysis]
122 Wu Y, Min J, Ge C, Shu J, Tian D, Yuan Y, Zhou D. Interleukin 22 in Liver Injury, Inflammation and Cancer. Int J Biol Sci 2020;16:2405-13. [PMID: 32760208 DOI: 10.7150/ijbs.38925] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
123 Hui RW, Mak L, Seto W, Yuen M. Role of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B. Curr Hepatology Rep 2020;19:293-301. [DOI: 10.1007/s11901-020-00523-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
124 Wei F, Kang D, Menéndez‐arias L, Liu X, Zhan P. Recent Developments in Small Molecular HIV‐1 and Hepatitis B Virus RNase H Inhibitors. Advances in Metallodrugs 2020. [DOI: 10.1002/9781119640868.ch9] [Reference Citation Analysis]
125 Arvind K, Ekta G, Rani N, Gaurav S, Kavita A, Manoj S, Sarin S. Performance evaluation of Xpert HBV viral load (VL) assay: Point-of-care molecular test to strengthen and decentralize management of chronic hepatitis B (CHB) infection.. [DOI: 10.1101/2020.05.31.20104760] [Reference Citation Analysis]
126 Lee I, Huang Y. Cessation of nucleos(t)ide analogues for patients with chronic hepatitis B in Taiwan: Risky but inevitable. Journal of the Chinese Medical Association 2020;83:515-516. [DOI: 10.1097/jcma.0000000000000317] [Reference Citation Analysis]
127 Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J Hepatol 2020; 12(5): 220-229 [PMID: 32547689 DOI: 10.4254/wjh.v12.i5.220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Liu H, Shi Y, Hayden JC, Ryan PM, Rahmani J, Yu G. Tenofovir Treatment Has Lower Risk of Hepatocellular Carcinoma than Entecavir Treatment in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Liver Cancer 2020;9:468-76. [PMID: 32999872 DOI: 10.1159/000507253] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
129 Zhang L, Wang Z. Circular RNA hsa_circ_0004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B. Virol J 2020;17:40. [PMID: 32188476 DOI: 10.1186/s12985-020-01314-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
130 Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. [PMID: 32206094 DOI: 10.1177/1759720x20912646] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
131 Oduwole HK, Ibrahim AI, Okoro SI. Modelling Vertical Transmission Of Hepatitis B Virus In An Age-Structured Population In The Presence Of Treatment In Nigeria. 2020 International Conference in Mathematics, Computer Engineering and Computer Science (ICMCECS) 2020. [DOI: 10.1109/icmcecs47690.2020.246991] [Reference Citation Analysis]
132 Muñoz BM, Ortega AM, Aldehuelo RS, García AG. Hepatitis víricas: virus de la hepatitis A, B y E. Medicine - Programa de Formación Médica Continuada Acreditado 2020;13:237-244. [DOI: 10.1016/j.med.2020.03.001] [Reference Citation Analysis]
133 Cheng K, Shi J, Liu Z, Jia Y, Qin Q, Zhang H, Wan S, Niu Z, Lu L, Sun J, Xue J, Lu C, Wei X, Guo L, Zhang F, Zhou D, Tang Y, Hu Y, Huang Y, Chen Y, Lau WY, Cheng S, Liu S. A panel of five plasma proteins for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma in individuals at risk. EBioMedicine 2020;52:102638. [PMID: 32014820 DOI: 10.1016/j.ebiom.2020.102638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
134 Irham LM, Wong HS, Perwitasari DA, Chou WH, Yang HI, Chang WC. Single-nucleotide polymorphism of rs7944135 (macrophage-expressed gene 1) is associated with hepatitis B surface antigen seroclearance in chronic hepatitis B infection: A cohort study. Medicine (Baltimore) 2019;98:e17936. [PMID: 31860948 DOI: 10.1097/MD.0000000000017936] [Reference Citation Analysis]
135 Munir R. Combination therapy against human infections caused by viruses. Combination Therapy Against Multidrug Resistance 2020. [DOI: 10.1016/b978-0-12-820576-1.00010-2] [Reference Citation Analysis]
136 Pyrski M, Mieloch AA, Plewiński A, Basińska-Barczak A, Gryciuk A, Bociąg P, Murias M, Rybka JD, Pniewski T. Parenteral-Oral Immunization with Plant-Derived HBcAg as a Potential Therapeutic Vaccine against Chronic Hepatitis B. Vaccines (Basel) 2019;7:E211. [PMID: 31835350 DOI: 10.3390/vaccines7040211] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
137 Zhang GL, Xu SC, Zeng J, Chen Z, Li YP, Zhang T, Gao ZL. Optimizing the Use of the Gamma-Glutamyl Transpeptidase-to-Platelet Ratio and Transient Elastography to Identify Liver Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease. Dis Markers 2019;2019:2585409. [PMID: 31885733 DOI: 10.1155/2019/2585409] [Reference Citation Analysis]
138 Liu X, Wan T, Dang S, Wang D, Jiang C, Su Y, Shen M, Tang X, Li X, Li B, Wen L, Feng Q. HLA-DQB1/DRB1 Alleles Associate with Traditional Chinese Medicine Syndrome of Chronic Hepatitis B: A Potential Predictor of Progression. Biomed Res Int 2019;2019:8146937. [PMID: 31871943 DOI: 10.1155/2019/8146937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
139 Chang L, Wang L, Ling N, Peng H, Chen M. Increase in liver γδ T cells with concurrent augmentation of IFN-β production during the early stages of a mouse model of acute experimental hepatitis B virus infection. Exp Ther Med 2020;19:67-78. [PMID: 31853274 DOI: 10.3892/etm.2019.8197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
140 Kostyusheva A, Brezgin S, Bayurova E, Gordeychuk I, Isaguliants M, Goptar I, Urusov F, Nikiforova A, Volchkova E, Kostyushev D, Chulanov V. ATM and ATR Expression Potentiates HBV Replication and Contributes to Reactivation of HBV Infection upon DNA Damage. Viruses 2019;11:E997. [PMID: 31683589 DOI: 10.3390/v11110997] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
141 Cerino A, Mantovani S, Mele D, Oliviero B, Varchetta S, Mondelli MU. Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection. Front Immunol 2019;10:2290. [PMID: 31608071 DOI: 10.3389/fimmu.2019.02290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
142 Van Hees S, Chi H, Hansen B, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Wong D, Sprengers D, Moreno C, Nevens F, Janssen H, Vanwolleghem T. Caucasian Ethnicity, but Not Treatment Cessation is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion. Viruses 2019;11:E687. [PMID: 31357522 DOI: 10.3390/v11080687] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
143 Park HS, Choe WH, Han HS, Yu MH, Kim YJ, Jung SI, Kim JH, Kwon SY. Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients: Pilot study. World J Gastroenterol 2019; 25(25): 3256-3267 [PMID: 31333316 DOI: 10.3748/wjg.v25.i25.3256] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
144 Cheung KS, Leung WK, Seto WK. Application of Big Data analysis in gastrointestinal research. World J Gastroenterol 2019; 25(24): 2990-3008 [PMID: 31293336 DOI: 10.3748/wjg.v25.i24.2990] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
145 Wang J, Qu B, Zhang F, Zhang C, Deng W, Dao Thi VL, Xia Y. Stem Cell-Derived Hepatocyte-Like Cells as Model for Viral Hepatitis Research. Stem Cells Int 2019;2019:9605252. [PMID: 31281392 DOI: 10.1155/2019/9605252] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
146 Mandato C, Guercio Nuzio S, Vajro P. Hepatitis B virus and the paediatric liver: waiting for news on the horizon. Acta Paediatr 2019;108:989-91. [PMID: 30868651 DOI: 10.1111/apa.14764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Zhang SF, Yang ZD, Huang ML, Wang ZB, Hu YY, Miao D, Dai K, Du J, Cui N, Yuan C, Li H, Li XK, Zhang XA, Zhang PH, Mi XM, Lu QB, Liu W. Preexisting chronic conditions for fatal outcome among SFTS patients: An observational Cohort Study. PLoS Negl Trop Dis 2019;13:e0007434. [PMID: 31136581 DOI: 10.1371/journal.pntd.0007434] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
148 Si J, Yu C, Guo Y, Bian Z, Meng R, Yang L, Chen Y, Jin J, Liu J, Guo Z, Chen J, Chen Z, Lv J, Li L; China Kadoorie Biobank Collaborative Group. Chronic hepatitis B virus infection and total and cause-specific mortality: a prospective cohort study of 0.5 million people. BMJ Open 2019;9:e027696. [PMID: 30967410 DOI: 10.1136/bmjopen-2018-027696] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
149 Pettersson JH, Myking S, Elshaug H, Bygdås KIE, Stene-Johansen K. Molecular epidemiology of hepatitis B virus infection in Norway. BMC Infect Dis 2019;19:236. [PMID: 30845915 DOI: 10.1186/s12879-019-3868-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
150 Zhou Y. Maternal immunisation and neonatal infection of hepatitis A or B virus. The Lancet Infectious Diseases 2019;19:238. [DOI: 10.1016/s1473-3099(19)30057-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]